Platelet count responses throughout EXTEND. (A) Median platelet counts with interquartile ranges (IQR) over time. (B) Weeks of continuous response at platelet thresholds of 30 × 109/L or more, or 50 × 109/L or more and twice baseline in the absence of rescue therapy. The “n” under each figure represents the total number of patients who had been exposed to eltrombopag for the indicated duration unless otherwise indicated. *Platelet count data were collected throughout the study as part of the complete blood count, weekly during the first 4 weeks, and at any dose change (eltrombopag or concomitant ITP medication). If a patient continued on a stable dose during any stage of the study for more than 4 weeks, platelets were assessed every 4 weeks. Because patients were not all assessed on the same schedule, the same patient is not necessarily shown at each assessment. Fewer than 15 patients had platelet counts at each assessment after week 250. †Number of patients with platelet counts of at least 50 × 109/L and at least twice baseline for the indicated number of weeks. ‡Number of patients with platelet counts of 30 × 109/L or more for the indicated number of weeks.
